Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 16, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
Pancreatic Cancer Non-resectablePancreatic Cancer MetastaticColorectal Cancer Metastatic
Interventions
DRUG

Medical Cannabis

The Early Cannabis group will be provided with 8 weeks of medical cannabis at no charge. Following 8 weeks of cannabis, the Early Cannabis group will be observed as per standard of care for the remaining 8 weeks. The Delayed Cannabis group will receive usual care for the first 8 weeks, and then be provided up to 8 weeks of medical cannabis at no charge for the second 8 weeks. Prior to receiving cannabis, patients must first be certified by a provider for eligibility to receive medical cannabis before registering with the Minnesota Medical Cannabis Program. Collective experience with precise dosage CBMs supports a pharmacist-guided titration protocol with robust patient input and close patient follow up. The treating pharmacist in the Minnesota Medical Cannabis Program thoroughly instructs patients on dose titration at the initial visit.

Trial Locations (1)

55426

RECRUITING

HealthPartners Cancer Research Center, Saint Louis Park

All Listed Sponsors
collaborator

University of Minnesota

OTHER

lead

HealthPartners Institute

OTHER